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Abstract
Originally identified as an oncogene activated by amplification in squamous cell carcinomas, several lines of evi-
dence now suggest that squamous cell carcinoma–related oncogene (SCCRO; aka DCUN1D1) may play a role in
the pathogenesis of awide range of human cancers including gliomas. SCCRO’s oncogenic function is substantiated
by its ectopic expression, resulting in transformation of cells in culture and xenograft formation in nudemice. The aim
of this study was to assess the in vivo oncogenicity of SCCRO in a murine model. Ubiquitous expression of SCCRO
resulted in early embryonic lethality. Because SCCRO overexpression was detected in human gliomas, its in vivo
oncogenic activity was assessed in an established murine glioma model. Conditional expression of SCCRO using
a replication-competent ASLV long terminal repeat with splice acceptor/nestin–(tumor virus-A) tv-a model system
was not sufficient to induce tumor formation in a wild-type genetic background, but tumors formed with increasing
frequency and decreasing latency in facilitated background containing Ink4a deletion alone or in combination with
PTEN loss. Ectopic expression of SCCRO in glial progenitor cells resulted in lower-grade gliomas in Ink4a−/− mice,
whereas its expression in Ink4a−/−/PTEN−/− background produced high-grade glioblastoma-like lesions that were
indistinguishable from human tumors. Expression of SCCRO with platelet-derived growth factor-beta (PDGF-β ) re-
sulted in an increased proportion ofmice forming glioblastoma-like tumors comparedwith those induced by PDGF-β
alone. This work substantiates SCCRO’s function as an oncogene by showing its ability to facilitate malignant trans-
formation and carcinogenic progression in vivo and supports a role for SCCRO in the pathogenesis of gliomas and
other human cancers.
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Introduction
The use of high-throughput, genome-wide screening tools has accel-
erated the definition of the cancer genome and has identified novel
aberrations in many different cancer types. Although informative,
the density and complexity of the aberrations identified by screening
studies make it difficult to identify those events that are relevant to
cancer pathogenesis. As genetic aberrations develop in random fashion
and are propagated in a Darwinian manner, those that occur in high
frequency and accumulate in cancers from diverse anatomic sites are
more likely to harbor cancer-related genes. Losses at 3p and 9p and
gains/amplifications at 3q and 11q13 are some examples of loci that
are aberrant in multiple cancer types [1–16]. Of particular interest is
amplification at 3q because it has been correlated with cancer pro-
gression and survival even after controlling for confounding variables
[3,13,17]. Moreover, because amplified genomic DNA is inherently
unstable, the high prevalence of 3q amplification in lung, head and
neck, esophageal, cervical, ovarian, vulvar, and urinary bladder cancers
supports its functional significance [1–16]. Several different candidate
genes have been identified within the 3q26.3 locus [5,18–20]. How-
ever, given the degeneracy of gene expression changes in amplified re-
gions combined with the lack of in vivo confirmation of oncogenic
function, the biological significance of individual genes that drive se-
lection for 3q26.3 amplification remains ill defined.
We identified squamous cell carcinoma–related oncogene (SCCRO)
within a subpeak of amplification at 3q26.3 using a systematic, posi-
tional cloning approach [12,21]. Supporting its candidacy as a target
activated by amplification at 3q, SCCRO is amplified and over-
expressed in a wide variety of human cancers, and its overexpression
is independently associated with an aggressive clinical course [21–24].
Consistent with its activation by amplification, ectopic expression of
SCCRO transforms NIH-3T3 cells and HaCaT cells, as evidenced by
their ability to form colonies in soft agar and xenografts in nude mice
[21]. In addition, we found that knockdown of SCCRO using RNAi or
antisense oligonucleotides resulted in apoptosis in tumor cell lines
overexpressing SCCRO, suggesting an “oncogene addiction” pheno-
type (Ganly, et al., unpublished data) [21]. We found that SCCRO
binds to neddylation components (CAND1, UBC12, and cullin fam-
ily of proteins). Further, our biochemical studies show that SCCRO
augments neddylation, a posttranslational modification of cullins,
which is a regulatory step in cullin RING ligase–mediated protein ubi-
quitination. Assessment of SCCRO function in cells and model organ-
isms suggests that it is essential for neddylation in vivo. Neddylation,
being an established pathway in cancer pathogenesis, supports SCCRO’s
function as an oncogene [25,26].
Despite the accumulated evidence, whether SCCRO plays a role in
human cancer pathogenesis remains to be established. As in vivo tumor
formation offers the strongest evidence for the functional importance
of an oncogene, we aimed to assess if overexpression of SCCRO results
in tumor formation in mice. We found that ubiquitous expression of
SCCRO resulted in lethality in mice. As such, we elected to use a con-
ditional somatic gene transfer model using a replication-competent
avian leukemia virus (RCAS) vector to deliver SCCRO into murine
cells that transgenically express the avian viral receptor (tv-a) [27]. Be-
cause we were not successful in delivering the transgene into oral and
lung epithelial cells, we screened other tumor types where SCCRO is
dysregulated. Because we found that SCCRO is overexpressed in hu-
man gliomas, we elected to use an established RCAS/tv-a model of mu-
rine gliomagenesis [27,28]. In this model, the nestin promoter was
used to drive tv-a expression (Ntv-a) in neuronal and glial progenitor
cells in the subventricular zone (SVZ) of mice, the cell of origin for
gliomas. Stereotactic injection of RCAS containing the desired trans-
gene in the SVZ allows conditional expression in glioma progenitor
cells [29]. We found that SCCRO expression did not induce glioma
formation by itself. In contrast, expression of SCCRO promoted glio-
magenesis in mice with facilitated genetic backgrounds containing
Ink4a deletion alone or in combination with PTEN loss. In addition,
coexpression of SCCRO promoted malignant progression of tumors
induced by platelet-derived growth factor-β (PDGF-β) in Ntv-a mice.
These findings suggest that SCCRO functions as an oncogene in vivo,
further validating its candidacy as a target activated by amplification
at 3q.
Materials and Methods
Plasmids
The coding sequence of murine SCCRO was cloned into pCDNA3-
HA (Invitrogen, Carlsbad,CA), EF1-α promoter containing pCDNA3.1
(Invitrogen), a CMV promoter containing pUSEamp (Upstate Biotech-
nology, Lake Placid, NY) by standard polymerase chain reaction (PCR)
cloning methods. Complementary DNA of SCCRO, polyoma mid-
dle T, and GFP were subcloned into RCAS vectors using the Gateway
in vitro recombination system (Invitrogen). The RCAS-PDGF-HA and
RCAS-Cre expression plasmids were developed as described previously
[29]. All constructs were confirmed by DNA sequencing.
Tumor Tissue
Primary brain tumors were collected from patients undergoing surgi-
cal resection, after obtaining informed consent and following institu-
tional guidelines. All tumor samples were terminally anonymized after
collection.Normal brain cortexwas obtained by autopsy of adult human
from a commercial source (Analytical Biological Services, Inc,Wilming-
ton, DE).
Immunoblot Analysis and Immunohistochemistry
Antibodies used were Cul1 (Zymed, San Francisco, CA), Cul3 (BD
Biosciences, San Jose, CA), tubulin (Calbiochem, San Diego, CA), HA
(Covance, Princeton, NJ), Olig2 (Chemicon, Temecula, CA), glial fi-
brillary acidic protein (GFAP; Bio Genex, San Ramon, CA), MIB1
(Dako, Carpinteria, CA), vimentin (Dako), and S100 (Dako). Antibody
against SCCRO was raised in rabbit and used as described earlier [21].
Secondary antibodies conjugated to horseradish peroxidase (Santa Cruz
Biotechnology, Santa Cruz, CA). For immunoblot analysis, the concen-
trations of antibodies used were according to the manufacturers’ speci-
fications. For immunohistochemical analyses, mouse brains were fixed,
paraffin-embedded, and processed essentially as described previously
[29]. Slides were stained with primary antibody overnight at 4°C. Ap-
propriate secondary biotin-conjugated antibody was applied for 1 hour
at room temperature. Peroxidase signal was developed using the ABC
kits (Vector Laboratories, Burlingame, CA).
Real-time Reverse Transcription–PCR Analysis
Real-time reverse transcription (RT)–PCR was performed essentially
as described earlier [21]. Melt curve analysis was performed after ampli-
fication [30]. The acquisition temperature was set 1°C to 2°C below the
Tm of the specific PCR product.Quantification of the target gene was in
comparison to a reference gene (18S rRNA). PCR primers and condi-
tions are as described earlier [21].
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In Vitro Embryonic Stem Cell Differentiation
Culture, transfection, and methods used for in vitro differentiation
and analysis of CJ7 ES cells into neurons were performed as previously
described [29].
Transgenic Mice
For pronuclear injection, the DNA from plasmid containing SCCRO
was sequence-verified, purified, and injected into F2 eggs obtained from
matings of (C57BL/6J × CBA/J) F1 mice. Approximately 200 to 250
injected eggs were transferred to pseudopregnant recipients for each
round of injection. For the development of chimera, ES cells were stably
transfected by electroporation, and antibody was selected. After confir-
mation of gene expression, transfected ES cells were injected into blas-
tocysts derived from the C57BL/6J inbred mice and transferred into
pseudopregnant recipients.
Transgene Expression in tv-a Transgenic Mice
RCAS constructs were propagated in chicken DF1 cells (CRL-12203;
ATCC, Manassas, VA), cultured as suggested by ATCC. Only DF1
cells that had been in culture for less than three passages after transfec-
tion with RCAS viral complementary DNA were used for infections.
Expression of transgenes in DF1 cells was confirmed by immunoblot
analysis. The delivery of transgenes by RCAS virus propagated in DF1
cells was confirmed by infecting primary brain cultures derived from
Ntv-a mice and by assessing the expression of transgenes in these cells
by immunoblot analysis. The function of RCAS-delivered SCCRO in
primary brain cultures was assessed by performing neddylation assays
as described [31]. Development and validation of mice expressing tv-a
under the control of a nestin promoter in wild type and facilitated back-
grounds have been described previously [29,32]. DF1 cells transfected
with RCAS vectors were trypsinized and suspended in approximately
50 μl of media and were aliquoted for injection. These cells were stereo-
tactically injected into the SVZ of mice as previously described [29]. Be-
fore injection, DF1 cells were lysed to confirm transgene expression by
immunoblot analysis. The brain from all mice was harvested, fixed in
formalin, embedded in paraffin, and subjected to histological and immu-
nohistochemical studies after sectioning as described previously [29]. All
specimenswere analyzed by an experienced pathologist in a blindedman-
ner. Tumors inmice were considered high grade if they had glioblastoma-
like features; all others were grouped as lower grade [33].
Statistical Analysis
Statistical analyses were performed using commercially available sta-
tistical software packages. Statistical significance was defined as a two-
tailed P ≤ .05. Descriptive statistics were used to summarize pertinent
study information. Fisher exact test was used for exact nonparametric
inferences. Survival curves were generated by the Kaplan-Meier method
and were compared using Gehan-Breslow-Wilcoxon test.
Results
Constitutive Expression of SCCRO Results in Embryonic
Lethality in Mice
Our prior work suggests overexpression resulting from amplification
activates SCCRO’s oncogenic function [21]. To determine whether
SCCRO functions as an oncogene in vivo, we aimed to develop amouse
model of ectopic SCCRO expression and to assess if this results in spon-
taneous tumor formation. Despite several attempts, no viable mice were
derived from pronuclear injection of embryos with constructs expressing
SCCRO under the control of ubiquitously active promoters (β-actin,
EF1-α, or CMV). This suggests that global expression of SCCRO re-
sults in embryonic lethality. To confirm these results and to determine
the timing and cause for lethality, we performed time dam experiments
after pronuclear injection of fertilized embryos with a plasmid contain-
ing SCCRO under the control of EF1-α promoter. After allowing suf-
ficient time for pronuclear fusion, the derived embryos were implanted
into pseudopregnant female mice. The transplanted females were
killed when the embryos were approximately E8.5 stage, and the em-
bryos were screened by PCR for the presence of transgene. No viable
embryos containing pCMV-SCCRO transgenic construct could be de-
tected, suggesting that those that harbored did not survive. In parallel
control experiments, pronuclear injection of embryos with empty vec-
tor resulted in grossly normal embryos.
As an alternative approach, we attempted to develop chimeric mice
by injecting blastocysts with embryonic stem (ES) cells stably expres-
sing SCCRO under the control of the EF1-α promoter. All experi-
ments were performed using two independent SCCRO-transfected
ES cell clones and empty vector-transfected ES cells as controls.
SCCRO-transfected ES cells showed higher rates of proliferation but
were otherwise phenotypically similar to vector-transfected cells (data
not shown). From a total of 120 blastocyst injections, only two mice
were born, both of which were less than 10% chimera based on coat
color. One of these mice died early from unknown causes, the other
died at 3 months of age with multiple tumors in the liver and kidney.
Transgenic SCCRO expression in the tumors in these mice was con-
firmed by PCR (data not shown). However, we were unable to gener-
ate additional chimeric mice, limiting the significance of the observed
findings. A control group, in which blastocysts were injected with ES
cells transfected with an empty vector, yielded normal mice that were
10% to 50% chimera based on coat color and had no obvious devel-
opmental defects or tumor formation. Although several possibilities
exist, one plausible explanation is that the hyperproliferative SCCRO-
transfected ES cells may outgrow native ES cells, which is substantiated
by analysis of blastocysts in culture showing a predominance of SCCRO-
transfected cells with progressive differentiation (data not shown). To
address this issue, we repeated the blastocyst injections with fewer ES
cells, as well as an independent SCCRO-transfected ES cell clone, which
also did not yield viable litters (data not shown). Combined, these find-
ings suggest that the misexpression of SCCRO is detrimental to murine
development, resulting in early embryonic lethality.
Conditional Expression of SCCRO in Epithelial Tissues
Because constitutive expression of SCCRO was lethal, we focused
our efforts toward the development of a conditional model of SCCRO
overexpression in mice. Given the high prevalence of 3q amplification
in squamous cell carcinomas (SCCs) of mucosal origin, we aimed to
develop a model for SCCRO overexpression in epithelial progenitor
cells that give rise to oral and/or lung SCCs in mice. However, primar-
ily due to the lack of a promoter that drives gene expression exclusively
in SCC progenitor cells, there are no well-established transgenic mod-
els for noncutaneous SCC in mice. Therefore, we first assessed it in an
RCAS/tv-a model to achieve selective gene expression in mucosal
keratinocytes, and if that was sufficient for tumorigenesis, RCAS viral
constructs containing either GFP or polyoma middle T antigen were
propagated inDF1 cells and were injected directly into the oral mucosa
of transgenic mice expressing the tv-a receptor under the control of the
keratin-5 or β-actin promoter. Despite varying the timing, amount,
and the sites of injection, we were unable to successfully infect oral
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Figure 1. SCCRO is expressed in developing murine neuronal tissue. (A) Transgenic mouse embryo (left-dorsal view; right-lateral view)
containing lac-Z under control of SCCRO promoter shows expression of β-galactosidase (lacZ) in developing brain (white arrow) and spinal
cord (black arrow) tissue. (B) Sagittal section (×20) showing SCCRO expression in nuclear layer of the neopallial cortex in embryonic (E16)
mouse brain (arrow). (C) Expression of SCCRO (right) in Oct4 (left)-expressing immature ES cells. (D) SCCRO-transfected ES cells show
increased neuron density (green) in controlled culture experiments. (E) ES cells transfected with SCCRO show increased number of cells
in S phase relative to vector-transfected. (F) SCCRO mRNA expression in human glioblastomas (n = 12) and normal brain tissue (n = 3)
by RT-PCR. (G) Immunoblot for SCCRO on normal brain tissue and human glioblastomas overexpressing SCCRO mRNA as determined
by RT-PCR.
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epithelial tissue (data not shown). Although the precise reasons remain
to be defined, RCAS virus, which preferentially infects actively prolif-
erating cells, may be limiting in the oral mucosa. In addition, the
mucosal epithelial layer is quite thin, making it difficult for the viral
inoculum to be delivered to the correct cells. Of note, a poorly differ-
entiated soft tissue tumor did develop in the masseter muscle of two
β-actin–tv-a mice injected with RCAS middle T antigen, confirming
that the RCAS construct was functional. Similar attempts to develop a
RCAS lung SCC model by transthoracic injection of the recombinant
virus were also unsuccessful.
SCCRO Is Expressed during Neuronal Development and Is
Overexpressed in Human Gliomas
Given our inability to develop a murine SCC model, we focused
on the identification of tumor systems with established approaches
for transgene expression in which SCCRO plays an oncogenic role.
The well-established RCAS-driven glioma model combined with the
high incidence of 3q amplification reported in gliomas (64%) led us to
investigate SCCRO’s function in gliomagenesis [34]. We first aimed to
determine whether SCCRO is active in gliomagenesis. Because cancer-
related genes are often dysregulated developmental genes, we first
assessed whether SCCRO function is relevant in neuronal tissues by
assessing its role in development using both in vivomurine and in vitro
neuronal differentiationmodel systems. Assessment of transgenicmouse
expressing LacZ under the control of the native SCCRO promoter sug-
gested that SCCRO is expressed and developmentally regulated in neu-
ronal tissues (Figure 1A). SCCRO was found to be expressed in the
developing mouse forebrain, midbrain, and hindbrain at the early stages
of neuronal development (Figure 1B). To substantiate our findings in
mice, we monitored the expression of SCCRO during differentiation
of ES cells to neurons [35,36]. In contrast to animal models, the differ-
entiation of ES cells allows analysis of the early stages of development
and assessment of the role of individual genes that may be involved in
the process. ES cells were cocultured and induced to differentiate to both
midbrain and hindbrain neuronal fate, and the expression of SCCRO
was assessed in different stages of differentiation. Midbrain cell fate
was confirmed in each experiment by assessing for tyrosine hydroxylase
and Tuj-1 expression. Immunofluorescence using polyclonal antibodies
against SCCRO showed pan-cellular distribution of SCCRO throughout
the course of differentiation of immature ES cells (Oct4 expressing) to
mature neuronal cells (TH and Tuj-1 expressing; Figure 1, C and D).
Quantitative analysis by real-time PCR showed that SCCRO expression
was highest at day 6 after initiation of ES cell differentiation and de-
clined thereafter. Ectopic expression of SCCRO in stably transfected
ES cells resulted in an increase in proliferative activity, as evidenced by
an increase in the number of cells in S phase on FACS analysis, bromo-
deoxyuridine incorporation (data not shown), and neuronal density
in controlled culture experiments (Figure 1E ). These data suggest
that SCCRO is developmentally regulated and that its overexpression
can induce proliferation in neural progenitor cells, suggesting that it
may impart growth advantages.
The high incidence of 3q amplification reported in human gliomas
(64%) led us to investigate if SCCRO is a target of 3q amplification in
these tumors. We assessed its messenger RNA (mRNA) and protein
levels in human glioblastomas. Overexpression of SCCRO mRNA
and protein was seen in primary gliomas relative to normal brain tissue
as detected by real-time RT-PCR and Western blot analyses (Figure 1,
F andG ). In addition, immunohistochemical analyses of tissue micro-
arrays showed that SCCRO is overexpressed (>2+ staining) in anaplas-
tic oligodendroma (13/42 cases, 31%), hemangioblastoma (4/12 cases,
33%), and glioblastoma (2/25 cases, 8%; data not shown). Combined,
these data support a role for SCCRO in human gliomagenesis.
Expression of SCCRO in Glial Cells Results in Oligodendroma
in Facilitated Genetic Backgrounds
To substantiate its role in gliomagenesis, we used theRCAS/tv-a system
to deliver and express SCCRO in the glial progenitor cells in the SVZ of
transgenicmice expressing tv-aunder the control of a brain-specific nestin
promoter (Ntv-a) [37]. As activation of SCCROmay be a late event in
malignant progression, we used a facilitated genetic background of
Ink4a−/− with and without PTEN using Ink4a/Arf −/−/ loxPPTENloxP
mice. RCAS-HA-SCCRO or RCAS-Cre recombinase was propagated
in DF1 cells. The ability of the RCAS virus to infect the primary brain
cells fromNtv-a transgenic mice and express the transgene (SCCRO and
Cre) was confirmed byWestern blot after infection of primary brain cul-
tures fromNtv-a transgenic mice (Figure 2A). As expected, expression of
Cre resulted in loss of PTEN (Figure 2B). To confirm that SCCRO re-
tained its known biochemical activity in primary brain cells, we per-
formed an in vitro neddylation assay essentially as described earlier
[31,38,39]. SCCRO promotes Cul1 and Cul3 neddylation, thereby es-
tablishing brain cells as a model to study its function (Figure 2C).
The oncogenic activity of SCCRO was tested in neonatal mice ex-
pressing Ntv-a, which were divided into five experimental groups
(Figure 3A). RCAS virus containing SCCRO and/or Cre was stereotac-
tically introduced into the SVZ of these mice. Ntv-a mice in groups 1
and 2 were infected with RCAS vector or RCAS-SCCRO, respectively.
Figure 2. Transgenic expression of SCCRO using the RCAS system.
(A) Immunoblot probed for SCCRO and HA showing the levels of
HA-SCCRO (top panel; upper band) and HA (middle panel) in primary
brain cell culture extracts from Ntv-a/Ink4a/Arf−/−/loxPPTENloxP mice
infectedwithRCAS-HA-SCCRO virus. (B) Extracts of same cells trans-
fected with Cre recombinase results in loss of PTEN expression. (C)
SCCRO functions to augment cullin neddylation inNtv-a Ink4a/Arf−/−
cell lysate. In vitro neddylation reaction containing primary brain cell
culture extracts from Ntv-a Ink4a/Arf−/−. Mice as a source of cullins
were incubated with neddylation components (E1, E2, ATP, and
Nedd8) for the indicated time in the absence or presence of recom-
binant SCCRO. Immunoblot of the reaction mixture probed for Cul1
(top) and Cul3 (bottom).
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Ntv-a/Ink4a/Arf −/−/ loxPPTENloxPmice in groups 3, 4, and 5were infected
with RCAS-Cre, RCAS-SCCRO, or both, respectively. Mice were killed
when they showed evidence of abnormal behavior, cephalomegaly, sei-
zures, or at 6 months if they remained asymptomatic. As expected, none
of the mice injected with DF1 cells expressing RCAS alone (group 1) or
RCAS-Cre (group 3) developed tumors. In addition, mice injected with
RCAS-SCCRO alone (group 2) did not develop tumors by 6 months.
Confirming that a longer latencywas not required for SCCRO to promote
tumorigenesis, an independent group of mice injected with RCAS-
SCCRO (n = 17) also did not develop tumors even at 12 months. Tu-
mors were seen inNtv-a/ Ink4a/Arf −/−/ loxPPTENloxPmice injected with
RCAS-SCCRO or RCAS-SCCRO with RCAS-Cre (groups 4 and 5, re-
spectively). Overall, 4 (21%) of 19mice injected with RCAS-SCCRO in
Ntv-a/ Ink4a/Arf −/−/ loxPPTENloxP background and 18 (45%) of 40 in-
jected with RCAS-SCCRO and RCAS-Cre (in Ink4a/Arf −/−/ loxPPTENloxP
background) developed tumors, suggesting that SCCRO can induce
tumor formation in a facilitated background (χ 2 test, P < .001). The
latency for SCCRO-induced tumor formation was shorter in Ink4a/
Arf −/−/PTEN−/− background (Figure 3B). Tumors in Ink4a/Arf −/− were
low grade (Figure 3C), with a lower proliferative index based on lower
mitotic rates and staining for MIB1 (<20% Ink4a/Arf −/− vs 50%-70%
forNtv-a/Ink4a/Arf −/−/loxPPTENloxP background). In contrast, tumors
that developed in the Ink4a/Arf −/−/PTEN−/− background were high
grade with palisading necrosis that was histopathologically indistin-
guishable from human glioblastomas (Figure 3C ). Immunophenotyp-
ing showed that all tumors in these experiments were oligodendromas
Figure 3. SCCRO overexpression promotes glioma formation in a facilitated genetic background. RCAS-SCCRO was stereotactically in-
jected into the SVZ of neonatal mice of various genetic backgrounds. (A) SCCRO induced tumor formation only in a facilitated genetic
background (groups 4 and 5; Fisher exact test, P < .001). (B) Disease-specific survival of Ntv-a mice. Loss of tumor suppressor PTEN is
associated with shorter latency (Gehan-Breslow-Wilcoxon test, P < .001). (C) Representative hematoxylin and eosin–stained sections
showing the histopathology of RCAS-SCCRO–induced tumor in two different genetic backgrounds: (i) Ntv-a Ink4a/Arf−/−mouse injected
with RCAS-SCCRO produces low-grade tumors and exhibits a subependymal location. (ii)Ntv-a Ink4a/Arf−/−, PTEN−/−mouse injectedwith
RCAS-SCCRO results in high-grade tumor that diffusely invades brain parenchyma and exhibits increased vascularity. (D) Immunohisto-
chemical analysis showing expression of Olig2 but not GFAP or nestin in brain tumor sections. (E) Agarose gel showing the PCR products
of DNA extracted from RCAS-HA-SCCRO–injected brain tissues using primers specific for HA-SCCRO (top) or PDGF-β (bottom), an unre-
lated gene as a negative control (lanes 1-5). (+) PCR products of the plasmid template containing HA-SCCRO (top) or PDGF-β (bottom) as
positive control. (−) PCRs without the template as negative control.
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because they expressed Olig2 but not GFAP, which is expressed in as-
trocytes (Figure 3D). As expected, no tumors developed in mice lacking
theNtv-a transgene regardless of the virus or combination of viruses with
which they were infected (data not shown). These observations suggest
that, although it is insufficient by itself, SCCRO promotes gliomagenesis
in a facilitated genetic background.
To determine whether SCCRO-mediated glioma formation is cell au-
tonomous, we assessed for nestin expression in tumors, which is a marker
for cells of glial origin. Immunohistochemical analyses of representative
tumors showed strong nestin expression in all samples (n = 15), reflecting
their glial lineage (Figure 3D). To establish a cause-and-effect relationship,
microdissected tumor samples, but not adjacent normal brain tissue,
showed the presence of RCAS-SCCRO as determined by PCR analyses
(Figure 3E , upper panel). As a negative control, we assessed for the pres-
ence of an unrelated oncogene, hPDGF-β, which was not detected in any
of the tumor samples tested (Figure 3E , lower panel ). These findings
suggest that SCCRO functions in a cell autonomous manner to pro-
mote oligodendromas in mice.
SCCRO Promotes Malignant Progression of
PDGF-Dependent Gliomas
PDGF-β is overexpressed and implicated inmultiple tumor types, in-
cluding gliomas [40]. Previous studies show that expression of PDGF-β
alone in nestin-positive progenitors is sufficient to induce glioma for-
mation in 60% of mice by 12 weeks [29]. Moreover, PDGF-β induces
tumor formation in a dose-dependent manner. Whereas low levels of
expression are associated with fewer tumors and low-grade histological
diagnosis, deletion of the inhibitory elements in the 5′UTR of PDGF-β
mRNA, which results in higher protein levels, results in the formation of
higher-grade gliomas and decreased tumor latency in mice [41]. More-
over, low-level expression of PDGF-β in facilitated genetic backgrounds
also results in the development of high-grade gliomas, recapitulating the
genetic complexity of human glioblastomas [42]. To assess if SCCRO
contributes to the progression of low-grade gliomas to glioblastomas, we
assessed the combined effects of RCAS-SCCRO and RCAS-PDGF-β
expression (low-level expression with a construct containing the entire
5′UTR) in Ntv-a mice. Although the latency and frequency of tumor
formation were not significantly changed, coexpression of SCCRO and
PDGF-β was associated with high-grade tumors, with 66% (5/6) of
these mice having glioblastoma-like histological diagnosis in contrast
to only 14% (1/7) of mice injected with PDGF-β alone (Fisher exact
test, P = .03; Figure 4A). Consistent with this observation, tumors in
mice resulting from coexpression of SCCRO and PDGF-β had increased
MIB1 expression, reflecting their higher rate of mitoses observed in these
tumors (Figure 4B). Furthermore, tumors in these mice were associated
with unique immunohistochemical features. Expression of vimentin
(4/6) and loss of S100 expression (3/6) were observed only in tumors
from mice infected with both RCAS-SCCRO and RCAS-PDGF-β
(Figure 4B). Loss of neural crest markers (S100) and expression of mes-
enchymal markers (vimentin) are consistent with dedifferentiated histo-
pathological findings in tumors resulting from the expression of SCCRO
and PDGF-β. These findings suggest that SCCRO contributes rather than
being the primary cause of the progression to malignant glioblastoma.
Discussion
Amplification at 3q, a common event in many human cancers, is asso-
ciated with progression to invasive cancer and survival, even after con-
trolling for confounding variables [12,14]. Given its high frequency and
clinical significance, identification of gene targets of 3q amplification has
been a focus of considerable interest. Because theminimal common am-
plified region at 3q is large, we used a systematic positional cloning ap-
proach to identify a subpeak at 3q26.3 that contained SCCRO [12,14].
Overexpression of SCCRO in benign transformed cells (NIH-3T3 and
HaCaT) resulted in malignant transformation based on in vitro and
xenograft assays in nude mice [21]. However, results from these experi-
ments are not sufficient to implicate SCCRO in cancer pathogenesis.
Because demonstration of in vivo oncogenic activity offers the strongest
evidence that a gene plays a role in cancer pathogenesis, we attempted to
develop transgenic mice expressing SCCRO under the control of consti-
tutive promoters to assess its oncogenic function. We found that over-
expression of SCCRO was lethal, likely at the preimplantation stage. As
such, we could not make any further conclusions about the cause for
lethality in thesemice. These results are consistent with the known func-
tion of SCCRO because dysregulation of neddylation pathway compo-
nent is associated with detrimental developmental effects.
Given the lethality observed in transgenic animals, we next elected to
develop a conditional model to assess the effects of SCCRO overexpres-
sion. Because 3q amplification has a predilection for SCC of mucosal
origin, our preference was to develop a model that allows overexpression
of SCCRO in epithelial cells. Considering no models were available that
allowed conditional expression of SCCRO in progenitor cells that give
rise to mucosal SCCs, we aimed to develop a novel model using the
RCAS/tv-a system. Despite trying many conditions, we were not able
to express SCCRO in sufficient levels in lung and oral mucosa of mice.
As such, we elected to look for othermodels that would allow assessment
of in vivo oncogenicity of SCCRO.
Figure 4. PDGF-β cooperates with SCCRO to produce poorly dif-
ferentiated glioblastoma. (A) Although no significant change in
overall incidence was observed, tumors induced by RCAS-PDGF-β
alone were primarily low grade, whereas those induced by in com-
bination with RCAS-SCCRO were high grade (Fisher exact test,
P = .03). (B) Brain sections of mice infected with RCAS-SCCRO and
RCAS-PDGF-β show a distinct immunohistochemical profile with in-
creased MIB1 expression and vimentin expression relative to those
infected with RCAS-PDGF-β alone. Loss of S100 expression was
seen in RCAS-SCCRO– and RCAS-PDGF-β–induced gliomas.
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Likemost cancers, glioma is a genetically complex disease withmultiple
pathways dysregulated. Gene amplification events are a key mechanism
for oncogene activation in human gliomas. These include EGFR (7p12),
PDGFRA (4q12), CDK4, and MDM2 (12q13-15) [43]. Genomic
screening studies have identified many other recurrent aberrations in
human gliomas [44]. Among these is 3q amplification, which is present
in as many as 64% of gliomas [34]. Because SCCRO plays a role in neu-
ronal development, its overexpression results in increased proliferation
in neuronal progenitors and overexpression in human gliomas, it repre-
sents a putative target of 3q amplification in human gliomas. As such, we
elected to test SCCRO’s in vivo oncogenic activity in a RCAS/tv-a murine
glioma model. In this model, the nestin promoter (Ntv-a) is used to drive
tv-a expression in neuronal and glial progenitor cells in the SVZ, the cell of
origin for gliomas. We found that RCAS-driven ectopic expression of
SCCRO was not sufficient to induce gliomagenesis on its own. This is
not surprising given that 3q amplification is a late event in cancer patho-
genesis, by which time many other genetic aberrations have already accu-
mulated in the cell. To try and recapitulate the temporal sequence and
genetic background in which 3q amplification may occur during glioma-
genesis, we assessed the effects of SCCRO expression in mice with a facil-
itated genetic background.We deleted Ink4a/Arf −/− and PTEN in NTv-a
in mice to facilitate cancer progression because these genes are known to
be mutated (≥30%) in human gliomas [45]. Whereas mutation of these
genes alone or in combination was not sufficient to induce tumor for-
mation, 21% of mice (n = 19) injected with RCAS-SCCRO in Ink4a/
Arf −/− background developed tumors. Expression of SCCRO in mice
deficient in both PTEN and Ink4a/Arf resulted in a shorter latency,
higher frequency 45% (n = 40), and higher grade of tumors in mice.
Similar results have been reported for EGFR, which formed gliomas
only when these tumor suppressor genes are mutated [46]. These find-
ings suggest either that SCCRO is weakly oncogenic or that it plays a
supportive rather than a direct role in cancer pathogenesis. These find-
ings are consistent with observations in oral SCC where amplification
at 3q and the associated activation of SCCRO is a late event in carcino-
genesis, occurring in the transition from in situ to invasive cancer [14].
In the time frame during which 3q amplification occurs, multiple ge-
netic aberrations have already accumulated in the fated cell. Combined,
these data implicate SCCRO as a candidate protooncogene that is ac-
tivated by amplification in human cancers.
Unlike SCCRO or EGFR, ectopic expression of PDGF-β alone is
sufficient to promote oligodendroglioma in neural progenitor cells.
However, PDGF-β expression in an Ink4a/Arf −/− background reduced
tumor latency and promoted progression toward a less-differentiated
phenotype [29]. Further substantiating its putative role in human glio-
magenesis, coexpression of SCCRO with PDGF-β was associated with
high-grade tumor. Consistent with this observation, these tumors had
increased MIB1 expression and acquired unique immunohistochem-
ical features, with vimentin expression and loss of S100 expression only
seen in SCCRO associated tumors. The higher grade and increased mi-
totic rate, combined with acquisition of unique immunohistochemical
features, suggest that SCCRO contributes to malignant progression of
PDGF-β–induced tumors. These findings suggest that SCCRO sup-
ports malignant progression in gliomagenesis. This may explain the
observation in oral and lung cancers where overexpression of SCCRO
is associated with a more aggressive clinical course and worse outcome.
Although the precise oncogenic mechanisms remain to be defined,
recent studies have shown that SCCRO promotes neddylation of cul-
lins, a regulatory step in protein ubiquitination [31]. Ubiquitination is
the principal process that controls proteosomal degradation and, as such
directly, affects diverse cellular functions such as cell cycle regulation,
signaling, and replication [47,48]. Given its function in neddylation,
SCCRO can affect the function of a wide variety of proteins by regulat-
ing their ubiquitination, a process that seems essential in carcinogenesis.
As an example, c-myc expression is not sufficient to induce tumor for-
mation in mice. Mutations that block ubiquitination of c-myc are more
oncogenic [49]. The high frequency and diversity of tumors in which
SCCRO is activated raises the possibility that dysfunction in neddylation
and, in turn, ubiquitination may be a key component in carcinogenesis.
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